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Background: Graves’ disease represents an autoimmune disease of the thyroid gland where surgery has an
important role in its treatment. The aim of our paper was to analyze the results of surgical treatment, the frequency
of microcarcinoma and carcinoma, as well as to compare surgical complications in relation to the various types
of operations performed for Graves’ disease.
Methods: We analysed 1432 patients (221 male and 1211 female) who underwent surgery for Graves’ disease at
the Centre for Endocrine Surgery in Belgrade during 15 years (1996–2010). Average age was 34.8 years. Frequency
of surgical complications within the groups was analyzed with nonparametric Fisher’s test.
Results: Total thyroidectomy (TT) was performed in 974 (68%) patients, and Dunhill operation (D) in 221 (15.4).
Carcinoma of thyroid gland was found in 146 patients (10.2%), of which 129 (9%) were a microcarcinoma. Complication
rates were higher in the TT group, where there were 31 (3.2%) patients with permanent hypoparathyroidism, 9 (0.9%)
patients with unilateral recurrent nerve paralysis and 10 (1.0%) patients with postoperative bleeding. Combined
complications, such as permanent hypoparathyroidism with bleeding were more common in the D group where there
were 2 patients (0,9%), while unilateral recurrent nerve paralysis with bleeding was more common in the TT group
where there were 3 cases (0,3%).
Conclusions: Frequency of complications were not significantly statistically different in relation to the type of surgical
procedure. Total thyroidectomy represents a safe and efficient method for treating patients with Graves’ disease, and
it is not followed by a greater frequency of complications in relation to less extensive procedures.
Keywords: Graves’ disease, Total thyroidectomy, Carcinoma, ComplicationsBackground
Graves’ disease (GD) represents an autoimmune disease
of the thyroid gland, which is manifested by excessive
production of hormones of the thyroid gland and is a
common cause of hyperthyroidism. GD is primarily treated
by anti thyroid drugs, and only in the case of failure of this
method of treatment are other types of therapy, such as the
use of radioactive iodine, taken into account [1]. In some* Correspondence: saskavalenta@sezampro.rs
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unless otherwise stated.countries, such as the United States, total thyroidectomy is
recommended only after treatment with radioactive iodine.
In Scandinavia, however, surgery with a low complication
rate plays an important role in the treatment of GD [2,3].
Surgical treatment is applied after exhausting other
treatment modalities, and represents a definitive treatment
where the reasons for surgery are various. The rate of
relapse after surgery is significantly lower than for treatment
with radioiodine, or anti thyroid drugs [4,5]. Antithyroid
drugs on one hand have good tolerance, but the rate of
recurrence of hyperthyroidism is up to 69% after termin-
ation of the treatment [6]. Radio ablation is a cost effectivehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Bojic et al. BMC Surgery  (2015) 15:39 Page 2 of 5method, good for patients at risk for surgery, but in order
to achieve euthyroidism it takes up to 6 month [7].
Surgical interventions, on the other hand, carried out
in patients with significant goitre and ophthalmopathy
give the fastest results and lead to the rapid regression
of the symptoms of hyperthyreosis [8].
Surgical treatment of GD achieves a quick and efficient
therapeutic effect and interventions performed by an
experienced surgeon are considered a safe procedure [1].
The surgical treatment of GD includes several modalities
of surgical operations such as bilateral subtotal lobectomy
(STT), unilateral total lobectomy and contralateral
subtotal lobectomy - Dunhill’s operation (D) and total
or near total thyroidectomy (TT).
The aim of our work was to analyze the results of surgical
treatment of patients with GD, the frequency of microcarci-
noma and carcinoma in patients who underwent surgery
for GD, as well as to compare surgical complications
(postoperative bleeding, postoperative hypoparathyroidism,
lesions of the recurrent laryngeal nerve) in relation to the
various types of operations performed for GD.
Methods
The research is a retrospective study in which data were
analyzed for patients surgically treated for GD at the
Centre for Endocrine Surgery, Clinical Centre Serbia in
the period 1996–2010. In this period a total of 1432
patients were operated for GD. Among the operated
patients there were significantly more women, 1211
(84.6%), while there were 221 men (15.4%); which roughly
corresponds to a ratio of 6 to 1. The average age of
the patients was 34.8 years (21 to 76 years).
All patients had previously been treated with thyrostatic
therapy (carbimazole, thiamazole, propylthiouracil) for a
period of 2 to 7 years, as well as with β-adrenergic
blockers. There were no patients who were previously
treated with radioiodine.
The diagnosis was based on clinical presentation, thyroid
hormones (T3, T4, TSH), and values of TSH-receptor
antibodies (increase above 1.0 IU/L).
Preoperatively, all patients achieved an euthyroid state
and were afterwards reviewed by an anaesthesiologist,
cardiologist and otorhinolaryngologist. All patients were
treated preoperatively with Lugol’s solution of iodine with
3–5 drops of iodine/a day for 2–3 weeks before surgery.
The study has been performed in accordance with
the Declaration of Helsinki. Ethical approval for our
study was obtained from institutional ethical committee of
Clinical Centre Belgrade, Serbia. All patients signed a
consent form for the surgical procedure which comprises
their consent for the storage and use of their data.
Data analyzed were patient sex, age, indications for
surgery, type of surgery, the incidence of carcinoma and
microcarcinoma and the frequency of complications(postoperative permanent hypoparathyroidism, unilateral
recurrent nerve paralysis and postoperative hematomas),
as well as the occurrence of associated complications
with the same patient.
Postoperative permanent hypoparathyroidism was con-
firmed 3 months after surgery and was defined by the
values of the parathyroid hormone below the lower limit
of the normal range of hormones (normal parathyroid
hormone from 10.0 to 65.0 pg/mL).
Unilateral recurrent nerve paralysis was confirmed by
the existence of unilateral vocal cord paralysis.
Postoperative hematoma was diagnosed over a period of
24 hours after surgery and required revision of haemostasis.
The analysis used data from the medical records,
operational protocols, reports on the histopathological
examinations and check-ups.
Obtained data (incidence of complications and the
incidence of associated complications), are presented
in tables with absolute numbers and the percentages
of corresponding structure in relation to the type of
applied surgical methods. Comparison between the
frequencies was performed with nonparametric Fisher’s test.
Statistical analysis was performed with software package
SPSS version 18 (SPSS Inc., Chicago, Illinois, USA) at the
level of statistical significance of p < 0.05.
Results and discussion
Table 1 shows the indications for surgical treatment of GD,
which included thyromegaly, confirmed nodule >1 cm in
diameter, ophthalmopathy and resistance to antithyroid
drug therapy. The indication for surgery in the majority of
831 (65%) patients operated for GD was thyromegaly,
while a smaller number, 143 patients (10%), were re-
lated to ophthalmopathy and an ultrasound diagnosed
nodule >1 cm.
Table 2 shows the distribution of patients according to
the type of operation. During the studied 15-year period,
in 974 patients (68%) the operation of choice for GD
was TT, while D was the operation of choice in only 221
(15.4%) patients. STT was performed only in the first
half of the studied period. With the development of
surgical technique this procedure was abandoned. At
Table 2 Distribution of operated according to the type of operation for Graves’ disease
Year 96 97 98 99 0 1 2 3 4 5 6 7 8 9 10 Σ %
TT 5 11 25 33 40 47 55 90 86 97 95 91 88 89 122 974 68
D 20 22 25 25 44 43 32 5 3 0 0 1 1 0 0 221 15.4
STT 65 60 54 30 15 8 5 0 0 0 0 0 0 0 0 237 16.6
Σ 90 93 88 99 98 92 95 89 89 97 95 92 89 89 122 1432 100
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left after STT is approximately 2 g on each side, while
after D its approximately 3 g on one side only.
Table 3 shows the incidence of thyroid cancer in
patients operated for GD. In 145 patients (10.2%)
with GD, definitive pathohistological examination
revealed thyroid cancer. Carcinomas of less than 1 cm
(microcarcinomas) were represented in 129 patients
(89.8%), while greater than 1 cm were present in 17
patients (1.2%). In the remaining 1286 patients (89.8%) we
did not observe the existence of cancer.
The incidence of complications in relation to the
type of operation is shown in Table 4. Postoperative
hypoparathyroidism, was most frequent in patients
who underwent TT, 31 (3.2%), whereas for patients
who had D it was present in 8 (3.6%), and 3 (1.3%)
for patients with STT.
Postoperative unilateral recurrent nerve paralysis was
reported in 9 (0.9%) patients who had TT, 1 (0.5%) who
had D, and 2 (0.8%) who underwent STT. Bilateral vocal
cord paralysis was not noted.
In patients who underwent TT postoperative bleeding
occurred in 10 (1%), with D in 1 (0.5%) and in the group
with STT in 2 (0.8%).
The incidence of complications was not statistically
significantly different in relation to the type of surgical
intervention (Fisher test, p > 0.05).
Frequency of associated complications is still lower
than the frequency of non associated complications:
permanent hypoparathyroidism with bleeding 5 (0.5%)
in the TT group; 2 (0.9%) in the D group and 1 (0.4%) in
the STT group. Post-operative unilateral recurrent
nerve paralysis with bleeding was reported in 3 (0.3%)
in TT group; 1 (0.5%) in the D group, and without
associated complications in the STT group. Permanent
hypoparathyroidism with postoperative unilateral recur-
rent nerve paralysis was present in 2 (0.2%) patients in theTable 3 The incidence of thyroid cancer in patients
operated for Graves’ disease
Tumor size N0 %
Tumor < 1 cm 129 9.0
Tumor > 1 cm 17 1.2
Without tumor 1286 89.8
Total patients with GD 1432 100TT group and without these associated complications in
the other groups (Table 4.).
The incidence of associated complications are also not
statistically significantly different in relation to the type
of surgery (Fisher test, p > 0.05).
By the end of the twentieth century, STT and D
were the most commonly applied operation in the
surgical treatment of GD on the grounds that the
complications (postoperative hypoparathyroidism and
recurrent laryngeal nerve palsy) were less frequent
compared to TT. At the beginning of the twenty-first
century, it became clear that STT and D were linked
to a high risk of relapse of GD [9,10] and surgeons in
specialized centres started to use TT as the operation
of choice in the treatment of GD. In addition to that,
the fact that TT removes the target organ for GD leads
to the elimination of the autoimmune stimulus and
improvement of the ophthalmopathy in these patients
[11]. Also, TT permanently removes the risk of cancer in
patients already having it, as TT represents an adequate
surgical intervention both for GD and for carcinoma of
the thyroid gland [9].
The series in our study represent uniform patient data
obtained from a single institution and operated by four
surgeons. According to available literature, our series are
the largest single series of patients operated for Graves’
disease in a single institution. A larger number of patients
was only shown in a study of Palit et al., but this study is a
meta–analysis of 35 clinical studies and included 7241
patients [2].
Our study showed that TT is a safe and effective method
of treating GD and has low complication rates.
Even when the initial treatment is surgery, the choice
of the primary treatment option depends on the adequate
cooperation of an endocrinologist, a specialist in nuclear
medicine and an endocrine surgeon [12]. The choice of an
adequate operation for GD is still the subject of debate
[13], although after the year 2000, TT has become the
treatment of choice for GD in many highly specialized
centres in the world [9,14,15].
Of the total number (1432) of treated patients with
GD significantly more were women 1211 (84.6%), while
there were 221 men (15.4%), which roughly corresponds
to the ratio 6 to 1. Analyzing our series of patients we did
not find any significant differences in relation to gender in
comparison to other authors [13,16]. The average age of
Table 4 Distribution of operated according to the type of operation for Graves’ disease and non associated and
associated postoperative complications
Method TT D STT
n % n % n % sig
Postoperative permanent hypoparathyroidism 31 3.2 8 3.6 3 1.3 ns
Unilateral recurrent nerve paralysis 9 0.9 1 0.5 2 0.8 ns
Postoperative bleeding 10 1.0 1 0.5 2 0.8 ns
Postoperative permanent hypoparathyroidism with postoperative bleeding 5 0.5 2 0.9 1 0.4 ns
Unilateral recurrent nerve paralysis with postoperative bleeding 3 0.3 1 0.5 0 0.0 ns
Postoperative permanent hypoparathyroidism with unilateral recurrent nerve paralysis 2 0.2 0 0.0 0 0.0 ns
Number of operated 974 100 221 100 237 100 /
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higher than data available in literature [2,16].
In the US, the number of patients with GD that are
surgically treated is small. According to the data of the
American Thyroid Association, surgery is, in the US, a
method of treatment in only 2% of patients with GD and
only in 7% of patients with GD and thyromegaly [17].
Total or near total thyroidectomy is recommended for
patients with ongoing thyroid cancer, those who refuse
radio-ablation as a therapeutic procedure, or have a life
threatening reaction to antithyroid drugs such as vasculitis,
agranulocytosis and liver failure [9].
Total thyroidectomy is recommended to patients with
Graves’ ophthalmopathy to eliminate the autoimmune
stimulus from the orbital antigens [11,18].
Due to a relatively low rate of complications for TT, com-
pared to less extensive procedures, many authors recom-
mended TT as the treatment of choice for GD [16,19-21].
In our study the most common indication for surgery
was thyromegaly (65%), followed by ophthalmopathy
and ultrasound diagnosed thyroid nodule >1 cm (10%).
In the study of Geeta et al., in a series of 103 patients
operated for GD, indications for surgery were 18% for
thyromegaly, 26% for identified thyroid nodule and 20%
for ophthalmopathy [14].
In our study, thyroid cancer was found, on definitive
histopathological examination, in 146 patients (10.2%) with
GD. Carcinomas smaller than 1 cm, or microcarcinomas,
were present in 129 patients (9%), while greater than 1 cm
were present in 17 patients (1.2%).
The incidence of thyroid cancer in GD by other authors
is from 0% to 21% [22,23]. In our study it was 10.2%, but
on a much larger number of patients than in the studies
of the cited authors Gabriele et al. (64) [22] and Calo et al.
(71) [23]. In the study by Geeta et al., thyroid cancer was
found in about 8% of studied patients, in a series of 103
patients operated for GD [14].
In the study by Mittendorf and McHenry in a series of
32 patients with GD, carcinoma was found in 6% of
operated patients [21], and the study of Pellegriti et al.found 4.7% of apparent clinically manifest carcinoma
and 3.3% of occult thyroid carcinoma in a series of 450
patients with GD [24].
In our study, postoperative permanent hypoparathyr-
oidism, was most frequent in patients who underwent
TT (3.2%), whereas it was lowest (1.3%) among patients
who underwent STT. Postoperative unilateral recurrent
nerve paralysis was most common in patients who had
TT (0.9%) and STT (0.8%), while it was much rarer in
patients who had D (0.5%). Postoperative bleeding was
more frequent in patients with TT (1%), than in patients
with D (0.5%) or STT (0.8%).
In the study of Palit et al., (meta-analysis of 35 clinical
studies with a total of 7241 patients) it was reported that
there were no significant differences for any violation of
the recurrent nerve (0.7% of STT compared to 0.9% for the
TT) or for postoperative permanent hypoparathyroidism
(1.0% for the STT compared to 0.9% for the TT) [2].
In the study of Wilhelm et al., in a series of 136 patients,
they recorded hematoma in the neck in only one patient
(0.8%) [10]; while the study of Jenkinks and Backer
states that TT performed by an experienced surgeon
has a rate of temporary recurrent nerve palsy of less
than 1%, while postoperative bleeding ranges between
0.3% and 0.7% [25].
The incidence of complications in patients operated for
GD in our series is low and is similar to the frequency of
complications in other specialized centres in the
world. About 65% of patients in the study of Mittendorf
and McHenry have developed transient postoperative
hypoparathyroidism [21] and the extent of surgical
intervention alone is taken as an important influen-
tial factor of transient and permanent postoperative
hypoparathyroidism [26].
The low incidence of complications in our study is
the reason why we advocate TT in the surgical treat-
ment of GD.
In relation to the type of surgery we did not find
any significant differences in any of the two groups of
complications.
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parathyroidism, and associated complications (hypopara-
thyroidism with bleeding), in patients who underwent D
is not a surprise. Although D operations are less radical
than TT, in recent years, D is performed as a coerced
surgical procedure for those patients in which we did not
reliably identify the recurrent nerve and/or preserved the
vascularisation of the parathyroid glands on the first side
of the operated thyroid gland.
Conclusion
If TT, as a surgical procedure performed in highly
specialized institutions, is not accompanied by a higher
rate of complications than less extensive surgery of the
thyroid gland then this operation has the advantage over
less extensive procedures for preventing relapse. There is
no need for reoperation as it represents an adequate
surgical treatment for thyroid cancer that can occur
in patients with GD. If performed by an experienced
surgeon, TT is the operation of choice for patients
undergoing surgical treatment for GD.
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